Kymera Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kymera Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Kymera Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 23.1 %, a 27.4% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 23.1 -8.74 -27.4% Sep 30, 2024
Q2 2024 29.1 +0.82 +2.9% Jun 30, 2024
Q1 2024 33.1 +5.41 +19.5% Mar 31, 2024
Q4 2023 37.7 +10.4 +38.3% Dec 31, 2023
Q3 2023 31.9 +2.32 +7.85% Sep 30, 2023
Q2 2023 28.3 -3.7 -11.6% Jun 30, 2023
Q1 2023 27.7 -10.1 -26.8% Mar 31, 2023
Q4 2022 27.2 -18.2 -40.1% Dec 31, 2022
Q3 2022 29.6 -26.5 -47.2% Sep 30, 2022
Q2 2022 32 -38.3 -54.5% Jun 30, 2022
Q1 2022 37.8 Mar 31, 2022
Q4 2021 45.5 Dec 31, 2021
Q3 2021 56 Sep 30, 2021
Q2 2021 70.3 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.